Valuation: Tsubota Laboratory Incorporated

Market Cap 629.38Cr 3.84Cr 3.38Cr 3.14Cr 2.88Cr 5.41Cr 370.26Cr 5.5Cr 37Cr 15Cr 182.03Cr 14Cr 14Cr P/E 2025
49.7x
P/E 2026 -9.95x
Enterprise Value 539.28Cr 3.29Cr 2.89Cr 2.69Cr 2.47Cr 4.64Cr 317.25Cr 4.71Cr 32Cr 12Cr 155.97Cr 12Cr 12Cr EV / Sales 2025
6.38x
EV / Sales 2026 33.4x
Free-Float
28.38%
Yield 2025 *
-
Yield 2026 -
17/06 Tsubota Laboratory Incorporated announced that it has received ¥4.129362 million in funding from Cantor Fitzgerald Europe CI
01/06 Tsubota Laboratory Incorporated announced that it expects to receive ¥4.129362 million in funding from Cantor Fitzgerald Europe CI
01/06 Tsubota Laboratory Incorporated signed a letter of intent to acquire MediProduce, Inc. from Eri Kubota for ¥150 million. CI
15/05 Tsubota Laboratory Incorporated Reports Earnings Results for the Full Year Ended March 31, 2026 CI
15/05 Tsubota Laboratory Incorporated Provides Non Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027 CI
13/02 Tsubota Laboratory Incorporated Provides Non Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2026 CI
13/02 Tsubota Laboratory Incorporated Reports Earnings Results for the Nine Months Ended December 31, 2025 CI
12/25/12 Tsubota Laboratory Incorporated Provides Earnings Guidance for the Fiscal Year Ending March 31, 2026 CI
17/25/17 Tsubota Laboratory Incorporated Revises Earnings Guidance for the Fiscal Year Ending March 31, 2025 CI
20/24/20 Tsubota Laboratory Incorporated Provides Earnings Guidance for the Fiscal Year Ending March 31, 2025 CI
19/22/19 Certain Common Stock of Tsubota Laboratory Incorporated are subject to a Lock-Up Agreement Ending on 19-DEC-2022. CI
20/22/20 Certain Common Stock of Tsubota Laboratory Incorporated are subject to a Lock-Up Agreement Ending on 20-SEP-2022. CI
23/22/23 Tsubota Laboratory Incorporated has completed an IPO in the amount of Ñ1.8048 billion. CI
Manager TitleAgeSince
President 71 01/02/2019
Chief Administrative Officer - -
Chief Tech/Sci/R&D Officer 65 01/01/2025
Director TitleAgeSince
Director/Board Member 71 01/02/2019
Director/Board Member 70 01/06/2020
Director/Board Member 55 01/06/2023
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 3.84Cr
+1.07%-3.49%-3.35%+10.44% 4.69TCr
+0.25%+1.65%+399.22%+634.87% 4.02TCr
-0.27%+4.45%+11.81%+65.64% 3.62TCr
+0.35%+0.87%+4.46%-10.16% 3.47TCr
+3.14%+1.02%+4.76%+40.92% 2.79TCr
-0.73%+11.84%+34.39%+134.36% 1.68TCr
+0.47%-2.74% - - 1.67TCr
+0.42%-5.52%-3.43%+9.03% 1.31TCr
-2.68%-2.49%-11.36%-33.61% 1.27TCr
Average +0.20%+0.83%+54.56%+106.44% 2.73TCr
Weighted average by Cap. +0.48%+0.91%+74.42%+136.27%

Financials

2025 2026
Net sales 135.7Cr 82.9L 72.81L 67.71L 62.13L 1.17Cr 80Cr 1.19Cr 8.04Cr 3.14Cr 39Cr 3.11Cr 3.04Cr 20Cr 12.22L 10.73L 10L 9L 17.21L 12Cr 17.47L 1.19Cr 46.3L 5.78Cr 45.87L 44.88L
Net income 20Cr 12.52L 11L 10.23L 9L 17.64L 12Cr 17.91L 1.21Cr 47.46L 5.93Cr 47.01L 46L -76Cr -46.49L -40.83L -37.97L -34.84L -65.47L -45Cr -66.48L -4.51Cr -1.76Cr -22Cr -1.75Cr -1.71Cr
Net Debt -144.8Cr -88.46L -77.69L -72.25L -66.3L -1.25Cr -85Cr -1.26Cr -8.58Cr -3.35Cr -42Cr -3.32Cr -3.25Cr -90Cr -55.04L -48.34L -44.96L -41.25L -77.51L -53Cr -78.71L -5.34Cr -2.09Cr -26Cr -2.07Cr -2.02Cr
Logo Tsubota Laboratory Incorporated
Tsubota Laboratory Inc is a Japan-based company mainly engaged in the research and development of new treatments for myopia, dry eye, and presbyopia. The Company operates with a B2B business model. The model generates revenue from lump-sum payments under joint research and development agreements and licensing agreements with partner companies, milestone payments, and royalties under post-commercialization (post-launch) loyalty agreements and creates new value by investing the profits in the new research. The Company is also engaged in the research and development of products for adults that treat depression and dementia, improve sleep and increase concentration.
Employees
22